Wara Samar
3rd February 2025
Lumicell’s LumiSystem Now in the US, Offering Real-Time Insights for Cancer Surgery
Lumicell has introduced LumiSystem to the US market, marking a significant advancement in real-time cancer detection during breast-conserving surgeries. This innovative system provides surgeons with immediate visualisation of cancerous tissue, improving the chances of complete tumour removal in a single procedure.
A New Era in Breast Cancer Surgery
The LumiSystem integrates two key components: the FDA-approved Lumisight optical imaging agent and the Lumicell Direct Visualisation System (DVS). Together, they enable real-time detection of residual cancer within the surgical cavity, helping to address a longstanding challenge in breast cancer surgery.
A primary goal of lumpectomy procedures is to remove cancerous tissue while preserving as much healthy tissue as possible. However, traditional surgical techniques do not offer direct assessment of residual cancer within the cavity, leading to a reliance on pathology reports. This limitation increases the likelihood of incomplete tumour removal, with an estimated 19% of cases deemed to have negative margins still harboring residual cancer. As a result, up to 36% of patients may require a second surgery to eliminate undetected cancerous tissue.
LumiSystem aims to reduce these repeat surgeries by offering immediate feedback to surgeons during the initial procedure. Its ability to illuminate cancerous tissue in real time enhances surgical precision, reducing the risk of missed cancer cells and improving patient outcomes. In the INSITE pivotal trial, the system demonstrated 84% diagnostic accuracy, with surgical results improving for 10% of patients by detecting cancer that would have otherwise gone unnoticed.
Expanding the Role of Real-Time Imaging
The commercial launch of LumiSystem represents a major step forward in breast-conserving surgery. By providing surgeons with a tool that enhances their ability to identify and remove cancerous tissue during the first procedure, Lumicell is addressing a critical need in surgical oncology.
Beyond breast cancer, the company is also exploring broader applications for its proprietary optical imaging agent, Lumisight, across various solid tumour types. This could pave the way for more effective cancer detection strategies across multiple surgical disciplines.
By reducing the need for additional surgeries, LumiSystem not only improves clinical outcomes but also enhances the patient experience. Fewer surgeries mean reduced physical and emotional stress, lower healthcare costs, and faster recovery times. The integration of real-time imaging in surgical oncology is a step towards a future where precision medicine plays a more prominent role in cancer treatment.
With the introduction of LumiSystem in the US, Lumicell is advancing surgical precision and efficiency, ultimately aiming to reduce the burden of repeat surgeries for patients. This innovation underscores the growing role of real-time imaging technologies in improving cancer treatment and surgical outcomes.
Join the Conversation at MedTech World Dubai
Join MedTech industry leaders, innovators, and key stakeholders on 23 and 24 February at MedTech World Dubai to explore the latest advancements, discuss emerging trends, and collaborate. Don’t miss this opportunity to be part of the conversation: register now!
